Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Considers Joining Swiss Vaccines Firm Berna With Chiron

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm would have to outbid a roughly $450 mil. bid from Dutch biotech company Crucell.
Advertisement

Related Content

Crucell Inks European Distribution Deal With Sanquin For Cofact
Crucell Inks European Distribution Deal With Sanquin For Cofact
Crucell Gains Contract Manufacturing Company With SBL Acquisition
Crucell Gains Contract Manufacturing Company With SBL Acquisition
Novartis Will Not Acquire Berna
Novartis Will Not Acquire Berna
Chiron Minority Shareholder Will Oppose Novartis Takeover
Second Time's The Charm: Novartis' New Bid Lures Chiron
Second Time's The Charm: Novartis' New Bid Lures Chiron

Topics

Advertisement
UsernamePublicRestriction

Register

PS061428

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel